A Venture Capital firm specializing in technologies, financials and healthcare industries is backed by an investment and hospital management team with more than 100 years and 80 years respectively of combined professional experiences.
The firm invests in three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with the firm’s domestic and foreign hospital & medical network.
The firm does not have management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based VC Firm Focuses on Medtech and Digital Health Investment Opportunities That Are Synergistic With Firm’s Investment and Hospital Network
30 JunHot Investor Mandate: Investment Firm is Most Interested in Therapeutics, But Invests Broadly Across All Life Science Sectors, Allocates Up to $10M Over Lifecycle
30 JunLife Sciences investment firm typically allocates up to $4M per initial investment. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach. The firm typically syndicates with major US venture capital firms. The firm is currently seeking new opportunities in the US, Canada, and Western Europe.
The firm puts 60% focus on therapeutics and 40% on medical devices, diagnostics and digital health. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor 20% interest in early-stage breakthrough bioengineering platforms with strong management teams. In medtech and digital health, the firm seeks to provide growth funding in technologically de-risked stories in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, medical services facilities and health tech, and biosimilars/generics/reformulations are not of interest.
The firm focuses on five key disease areas: oncology, autoimmune diseases, anti-infectives, CNS/pain, and women’s health. In oncology and autoimmune diseases, the firm seeks therapies with novel mechanisms of action, human data and signs of efficacy, and it also considers new generation molecular diagnostics technologies. In anti-infectives, the firm is considering early stage assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and a clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.
The firm is looking for high-caliber serial entrepreneurs with an unmatched track-record of success and strong credibility. The firm does not typically take a board seat in the companies it invests in.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Invests in Devices, Diagnostics, and Digital Health Companies in North America and Europe, Preferring Technologies With Digital Component
30 JunA firm based in Western Europe focuses on investing in digital health, devices and diagnostics technologies. Though an early investor, the firm looks for companies that have some proof of concept data. The firm will consider investments in North America and Europe. The firm generally looks to invest between 100K-2M EUR in their portfolio companies.
The firm will invest in digital health as well as diagnostics and devices as well as regenerative medicine technologies. For diagnostics and devices, the firm prefers companies with a digital component. In addition, the firm prefers devices without complex regulatory requirements. The firm is agnostic with regards to indication.
The firm is willing to lead or co-invest. Generally, the firm prefers to have a board or an observer seat after investing. Within the life sciences, the firm prefers to invest in teams with industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
RESI Boston Pitch Applications Now Open
23 JunBy Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
One of the best parts of RESI returning to an in-person format after more than two years is the return of the live pitch session! RESI Boston returns in-person September 21-22, with an additional day of dedicated-digital partnering September 23. Applications to pitch for the Innovator’s Pitch Challenge (IPC) are now open until Friday, August 12! The IPC was created to respond to the need for a digital pitch format. Now it has been modified to bring the value and function to an in-person format.
What Is It?
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. Participating companies pay to host their company materials on the Live Agenda and participate in the live pitch session.
How Does It Work?
Pitching companies will have a dedicated webpage on the RESI Live Agenda, which greatly increases visibility to investors and other registered attendees. Companies can share their marketing collateral such as their slide deck, executive summary, optional pitch video, and more.
Each pitching company will be assigned to an IPC session, with each session featuring four companies, grouped together based on similar sector and/or technology. Companies will be given four minutes to pitch, followed by an additional ten minutes of Q&A and feedback from the judging panel.
Who Should Apply?
Early-stage life science companies actively raising seed capital ($25K – 2M), Series A ($2 – 10M), or Series B ($10 – 50M) use the IPC to get in front of the panel of qualified investor judges in their market segment and pitch their company and product. Early-stage companies are encouraged to apply and submit their pitch deck and executive summary.
Branding Opportunities at RESI Boston
23 JunBy Candice He, Vice President of Business Development, Global Investment Strategist, LSN
RESI returns to an in-person format after more than two years this September, and now is the time to start planning exhibit and sponsorship engagements to hundreds of RESI attendees at the hub of life science industry – Boston, MA. Whether service providers increasing deal pipeline, big pharma sourcing technology assets, or just looking to connect with early-stage startups at pre-clinical/phase I stage, RESI Boston is the place to get started! With 350+ life science investors and big pharma, 200+ early-stage company executives, and dozens of delegations from global incubators, universities, and organizations, there’s no better place to connect with ideal partners and start those meaningful conversations.
To showcase products and services, RESI offers a range of sponsorship opportunities, including dedicated workshops, exhibition tables, and newsletter interviews. Prominent logo displays throughout both the digital platform and onsite signage will greatly increase brand visibility, as well as program guide ads, onsite meal or material sponsorship, session signage, pitch judging, and more.
Check out sponsorship opportunities for RESI Boston, September 21-23. For more information about sponsorship, advertising, and exhibit opportunities, contact our dedicated BD team. We look forward to helping you meet your goals!
Tech Hub Exposure at RESI Boston
23 JunBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
RESI Boston returns to an in-person format this September, and if you’re part of a tech hub, RESI is the place to be! Join RESI’s global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship journey. Recently, RESI has hosted tech hubs ranging from National Institute of Aging (NIA), The Massachusetts Medical Device Development Center (M2D2), Government of Ontario, Yale Ventures, and more.
Through RESI partnership, tech hub startup constituents gain access to resources beyond partnering with investors and strategic partners, such as the Life Science Nation (LSN)’s Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneurial Immersion Courses, to help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.
At RESI Boston, tech hub organizations and their startup constituents who’ve raised less than $2M can utilize:
- 50% discount for startup constituent registration (startup must be from LSN’s tech hub partners)
- Complimentary tech hub staff registration
- Group Fundraising Investor Database Package (3 startups minimum): 4-month access to the Investor Database
- Dedicated onsite-only Innovator’s Pitch Challenge (IPC) session
- Exhibition space
If you’re a member of a tech hub or looking to add value to your members, reach out to see which offerings best fit your needs. From lab to clinic, and providers to patients, LSN is accelerating the growth and success of companies emerging from tech hubs.
For more information about tech hub offer, please contact Erika Wu, Business Development Manager, Global Tech Hubs at e.wu@lifesciencenation.com.
Hot Investor Mandate: Corporate VC Firm Invests Up to $10M in Therapeutics and Digital Health in Areas that Strategically Align with Parent Company’s Interest Areas
23 JunA corporate venture capital firm with offices in USA and Western Europe invests from an evergreen fund. The firm interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $10 million over the life of an investment. The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments; the fund’s allocations are ‘no strings attached’. The firm considers opportunities globally but focuses on Europe, Middle East and North America.
The firm is strategically mandated to invest in opportunities beyond the corporate’s core areas of business. The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology), but will also consider opportunities in other indication areas that lie outside of the corporate’s present core therapeutic fields. Areas in which the parent company has strength, such as respiratory disorders and diabetes, will generally not receive investment from the firm. The firm generally invests in preclinical assets.
The firm invests in technologies of strategic importance to the parent company. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 